



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

10 September 2025
EMA/CAT/291880/2025
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 10-12 September 2025

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

10 September 2025, 14:00 – 18:30

11 September 2025, 09:00 – 18:30

12 September 2025, 09:00 – 13:00

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.3.1.	Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein - Orphan - EMEA/H/C/006525	5
2.4.	Day 120 list of questions	6
2.4.1.	Onasemnogene abeparvovec - Orphan - EMEA/H/C/006498.....	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.6.1.	Autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded - EMEA/H/C/006563.....	6
2.7.	New applications	6
2.8.	Withdrawal of initial marketing authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.9.1.	JELRIX - Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594.....	6
2.10.	GMP and GCP inspections requests.....	7
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2771.....	7
2.11.2.	Ebvallo - Tabelecleucel - Orphan - EMA/VR/0000284818	7
2.11.3.	Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/VR/0000270071.....	7
2.11.4.	Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000282599.....	7
2.11.5.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000281226	8
2.11.6.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000285085	8
2.11.7.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000272240	8
2.11.8.	Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000284307.....	8
2.11.9.	Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMA/VR/0000282021	8
2.11.10.	Casgevy - Exagamglogene autotemcel - Orphan - EMA/VR/0000264854.....	9
2.11.11.	Vyjuvek - Beremagene geperpavec - Orphan - EMA/VR/0000284864	9

2.11.12.	Imlygic - Talimogene laherparepvec - Orphan - EMA/VR/0000258245	9
2.11.13.	Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMA/VR/0000280312	9
2.12.	Extension applications	9
2.13.	Other Post-Authorisation Activities	9
2.13.1.	Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000285196	9
2.13.2.	Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000280380	10
2.13.3.	Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000248926	10
2.13.4.	Tecartus - Brexucabtagene autoleucel - Orphan - EMA/PAM/0000273165	10
2.13.5.	Libmeldy - Atidarsagene autotemcel - Orphan - EMA/PAM/0000286209	10
2.13.6.	Tecartus - Brexucabtagene autoleucel - Orphan - EMA/R/0000278705	10
2.13.7.	Libmeldy - Atidarsagene autotemcel - Orphan - EMA/R/0000257479	11
2.14.	Companion diagnostics - initial consultation	11
2.15.	Companion diagnostics – Follow-up consultation	11
3.	Certification of ATMPs	11
3.1.	Opinion	11
3.2.	Day 60 Evaluation Reports	11
3.3.	New Applications	11
4.	Scientific Recommendation on Classification of ATMPs	11
4.1.	New requests – Appointment of CAT Coordinator	11
4.1.1.	CD4+CD25+CD127-MOG-CAR+ T regulatory cells	11
4.1.2.	Non-replicating recombinant adeno-associated viral vector serotype hu68 (AAVhu68), containing a codon-optimized human survival motor neuron 1 (SMN1) gene	12
4.2.	Day 30 ATMP scientific recommendation	12
4.2.1.	Lentiviral vector encoding for short hairpin RNA (shRNA) sequences down-regulating human leukocyte antigen (HLA) class I and HLA class II by targeting key messenger RNAs (mRNAs)	12
4.2.2.	Viable, allogeneic, in vitro expanded human corneal keratocytes on an adhesive scaffold matrix	12
4.3.	Day 60 revised scientific recommendation (following list of questions)	12
4.4.	Finalisation of procedure	12
4.5.	Follow-up and guidance	12
5.	Scientific Advice	12
5.1.	New requests - appointment of CAT Rapporteurs	13
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	13
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	13
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	13
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting	13
5.4.	Final Advice Letters for procedures finalised the previous month	13

6.	Pre-Authorisation Activities	13
6.1.	Paediatric investigation plans.....	13
6.2.	ITF briefing meetings in the field of ATMPs	14
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	14
6.3.1.	Month 0 - Start of the procedure	14
6.3.2.	Month 1 – Discussion of eligibility	14
6.3.3.	Month 2 – Recommendation of eligibility.....	14
6.3.4.	Ongoing support.....	14
7.	Organisational, regulatory and methodological matters	14
7.1.	Mandate and organisation of the CAT	14
7.1.1.	CAT membership	14
7.1.2.	Vote by proxy	14
7.1.3.	Onboarding document for new CAT members/alternates.....	14
7.1.4.	CAT Strategic Review & Learning meeting (SRLM) under the Danish presidency	14
7.2.	Coordination with EMA Scientific Committees.....	15
7.2.1.	GIREX report	15
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	15
7.4.	Cooperation with the EU regulatory network.....	15
7.5.	Cooperation with international regulators.....	15
7.5.1.	Feedback from (International Pharmaceutical Regulators Programme) IPRP cell and gene therapy working group	15
7.5.2.	ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic	15
7.5.3.	Opening procedures at EMA to non-EU authorities (OPEN) Framework.....	15
7.6.	CAT work plan	16
7.6.1.	CAT workshop on gene editing	16
7.6.2.	State-of-play on AI activities.....	16
7.7.	Planning and reporting	16
7.8.	Others	16
7.8.1.	REVAMP – Survey on first-hand experience.....	16
7.8.2.	Pre-Submission Interactions Group	16
8.	Any other business	16
9.	Explanatory notes	17

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 10-12 September 2025. See August 2025 and September 2025 CAT minutes (to be published post September 2025 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 10-12 September 2025 meeting

1.3. Adoption of the minutes

CAT minutes for 12-14 August 2025 meeting

CAT minutes for 10-12 September 2025 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein - Orphan - EMEA/H/C/006525

Fondazione Telethon Ets; Treatment of patients with Wiskott-Aldrich syndrome (WAS)

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 16.04.2025.

2.4. Day 120 list of questions

2.4.1. Onasemnogene abeparvovec - Orphan - EMEA/H/C/006498

Novartis Europharm Limited; Treatment of 5q spinal muscular atrophy (SMA)

Scope: Day 120 list of questions

Action: for adoption

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded - EMEA/H/C/006563

Treatment of melanoma

Scope: Request for clock stop extension

Action: for discussion

List of questions adopted on 18.07.2025

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

2.9.1. JELRIX - Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594

TETEC Tissue Engineering Technologies AG; Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV

Scope: for appointment of re-examination Rapporteurs and re-examination timetable

Action: for discussion

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2771

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Erneholm

Scope: Safety, opinion

Submission of an updated RMP version 4.3 for Tecartus and version 11.1 for Yescarta following the PRAC recommendation for the secondary malignancy of T-cell origin signal (EPITT no: 20040), and of a PASS protocol for a framework for the sampling and testing of secondary malignancies of T-cell origin.

Action: for adoption

Request for supplementary information adopted on 16.05.2025, 24.01.2025.

2.11.2. Ebvallo - Tabelecleucel - Orphan - EMA/VR/0000284818

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, request for supplementary information

Action: for adoption

2.11.3. Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/VR/0000270071

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Quality, opinion

Action: for adoption

2.11.4. Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000282599

Novartis Europharm Limited

Rapporteur: Rune Kjeklen

Scope: Quality, request for supplementary information

Action: for adoption

2.11.5. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000281226

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.11.6. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000285085

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.11.7. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000272240

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, request for supplementary information

Action: for adoption

2.11.8. Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000284307

Novartis Europharm Limited

Rapporteur: Rune Kjekken

Scope: Quality, request for supplementary information

Action: for adoption

2.11.9. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMA/VR/0000282021

Fondazione Telethon Ets

Rapporteur: Sol Ruiz, PRAC Rapporteur: Liana Martirosyan

Scope: Clinical

Submission of the final report from study STRIM-005. This is a non-interventional methodology study to investigate the utility of retroviral insertion site analysis in samples from subjects treated with Strimvelis gene therapy. The RMP version 8.0 has also been submitted.

Action: for adoption

2.11.10. Casgevy - Exagamglogene autotemcel - Orphan - EMA/VR/0000264854

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.11.11. Vyjuvek - Beremagene geperpavec - Orphan - EMA/VR/0000284864

Krystal Biotech Netherlands B.V.

Rapporteur: Joseph De Courcey

Scope: Quality, request for supplementary information

Action: for adoption

2.11.12. Imlygic - Talimogene laherparepvec - Orphan - EMA/VR/0000258245

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Quality, opinion

Action: for adoption

2.11.13. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMA/VR/0000280312

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, request for supplementary information

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000285196

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: PAM

Action: for adoption

2.13.2. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000280380

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: PAM

Action: for adoption

2.13.3. Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000248926

CSL Behring GmbH

Rapporteur: Silke Dorner, PRAC Rapporteur: Bianca Mulder

Scope: PAM, HCP survey, request for supplementary information

The MAH submitted a PASS protocol (version 1.0), which covers a Healthcare Professional survey (HCP) to assess the effectiveness of the additional Risk Minimisation Measures (aRMM) for Hemgenix (etranacogene dezaparvovec).

Action: for adoption

2.13.4. Tecartus - Brexucabtagene autoleucel - Orphan - EMA/PAM/0000273165

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: PAM, Protocol update (mainly editorial and mantle cell lymphoma milestones) for study KT-EU-472-6036.

Action: for adoption

2.13.5. Libmeldy - Atidarsagene autotemcel - Orphan - EMA/PAM/0000286209

Orchard Therapeutics (Netherlands) B.V.

Rapporteur: Emmely de Vries

Scope: PAM

Action: for adoption

2.13.6. Tecartus - Brexucabtagene autoleucel - Orphan - EMA/R/0000278705

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: Renewal - 1 year

Action: for adoption

Orchard Therapeutics (Netherlands) B.V.

Rapporteur: Emmely de Vries, Co-Rapporteur: Barbara Bonamassa, PRAC Rapporteur: Gabriele Maurer

Scope: Renewal - 5 year

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. CD4+CD25+CD127-MOG-CAR+ T regulatory cells

Treatment and prevention of progression of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Amyotrophic Lateral Sclerosis (ALS), Primary Progressive Multiple Sclerosis.

Scope: for nomination of CAT coordinator

Action: for adoption

- 4.1.2. Non-replicating recombinant adeno-associated viral vector serotype hu68 (AAVhu68), containing a codon-optimized human survival motor neuron 1 (SMN1) gene
-

Treatment of Spinal Muscular Atrophy (SMA)

Scope: for nomination of CAT coordinator

Action: for adoption

4.2. Day 30 ATMP scientific recommendation

- 4.2.1. Lentiviral vector encoding for short hairpin RNA (shRNA) sequences down-regulating human leukocyte antigen (HLA) class I and HLA class II by targeting key messenger RNAs (mRNAs)
-

Ex vivo genetic modification of lung grafts prior to transplantation in patients

Scope: ATMP scientific recommendation

Action: for adoption

- 4.2.2. Viable, allogeneic, in vitro expanded human corneal keratocytes on an adhesive scaffold matrix
-

Treatment of deep or perforating corneal defects

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

No items

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	01-04.09.2025
- Appointment of CAT Peer Reviewers:	10-12.09.2025
- SAWP first reports:	22.09.2025
- CAT Peer Reviewer comments (NC & C):	26.09.2025
- CAT Peer Reviewer comments (Q):	01.10.2025
- Discussion at SAWP:	29.09-02.10.2025
- Discussion at CAT and feedback to SAWP:	08-10.10.2025

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	29.09-02.10.2025
- Appointment of CAT Peer Reviewers:	08-10.10.2025
- SAWP first reports:	20.10.2025
- CAT Peer Reviewer comments (NC & C):	24.10.2025
- CAT Peer Reviewer comments (Q):	29.10.2025
- Discussion at SAWP:	27-30.10.2025
- Discussion at CAT and feedback to SAWP:	05-07.11.2025

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

No items

5.4. Final Advice Letters for procedures finalised the previous month

No items

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start: 01-04.09.2025

SAWP recommendation: 02.10.2025

CAT recommendation: 10.10.2025

CHMP adoption of report and final recommendation: 16.10.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. Onboarding document for new CAT members/alternates

Scope: Welcoming document to assist new members/alternates

Action: for information

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Danish presidency

Scope: Preparation for the meeting

CAT: Martin Bronislaw Oleksiewicz

Action: for information

7.2. Coordination with EMA Scientific Committees

7.2.1. GIREX report

Analysis of requests for clock-stop extensions and feedback from GIREX

Action: for discussion

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. Feedback from (International Pharmaceutical Regulators Programme) IPRP cell and gene therapy working group

CAT: Pille Saalik

Scope: Teleconference of 22 July 2025

Action: for information

7.5.2. ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic

CAT: Ilona Reischl

Scope: Change of date to 02.10.2025 and call for topics

Action: for information

7.5.3. Opening procedures at EMA to non-EU authorities (OPEN) Framework

CAT: Ilona Reischl

Scope: proposal to broaden the scope of the Open framework to include ATMPs

Action: for discussion

For more information of the OPEN framework, see [here](#)

7.6. CAT work plan

7.6.1. CAT workshop on gene editing

Scope: Informing the members of the upcoming event

Action: for information

7.6.2. State-of-play on AI activities

Scope: Stock-take on AI section of CAT workplan, update on EMRN initiatives around knowledge mining, AI literacy and change management

Action: for information

7.7. Planning and reporting

No items

7.8. Others

7.8.1. REVAMP – Survey on first-hand experience

A survey has been circulated to collect feedback from users (members, assessors) on their initial experience with the new REVAMP template / process. This is a call for your support in disseminating to all relevant assessors/contributors and filling the survey if you were involved in one of those procedures

Action: for information

7.8.2. Pre-Submission Interactions Group

Update to the CAT on the activities of the Pre-submission Interaction Group, which is focused on enhancing pre-submission interactions to optimise submission readiness, anticipate assessment challenges, reduce premature applications, and promote alignment on submission timelines.

Action: for information

8. Any other business

No items

Date of next CAT meeting:

08-10 October 2025

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations in Committee CMD documents and in relation to EMA regulatory activities


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/